A single dose of citalopram increases fear recognition in healthy subjects
- PMID: 17259206
- DOI: 10.1177/0269881106074062
A single dose of citalopram increases fear recognition in healthy subjects
Abstract
We have previously shown that a single dose of intravenous citalopram in healthy volunteers enhances the detection of fearful facial expressions, suggesting an effect of acute selective serotonin re-uptake inhibitor (SSRI) treatment on the processing of anxiety-related stimuli. The aim of the present study was to confirm and extend this finding by studying the effects of a single dose of oral citalopram on a range of tasks designed to assess different aspects of emotional processing. A total of 32 healthy volunteers were randomly allocated to double-blind treatment with either citalopram 20 mg orally or placebo. Participants then completed a series of tasks assessing emotional aspects of attention (visual-probe task), perception (categorization of facial affect), memory (emotional memory task) and reactivity to threat (emotion potentiated startle). Relative to placebo-treated subjects, participants treated with citalopram demonstrated improved recognition of fearful faces and increased baseline startle response. However, the citalopram group also showed an attentional bias towards positive words. Our data suggest that acute oral citalopram increases the processing of anxiety-related stimuli in healthy volunteers. This mechanism could underlie the known tendency of SSRIs to increase anxiety in patients early in treatment. Our data also suggests that some of the positive biases in emotional processing produced by SSRI treatment might be detectable at the beginning of treatment.
Similar articles
-
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.Am J Psychiatry. 2004 Jul;161(7):1256-63. doi: 10.1176/appi.ajp.161.7.1256. Am J Psychiatry. 2004. PMID: 15229059 Clinical Trial.
-
Early effects of mirtazapine on emotional processing.Psychopharmacology (Berl). 2009 May;203(4):685-91. doi: 10.1007/s00213-008-1410-6. Epub 2008 Nov 25. Psychopharmacology (Berl). 2009. PMID: 19031070 Clinical Trial.
-
Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans.J Psychopharmacol. 2013 May;27(5):435-43. doi: 10.1177/0269881112472558. Epub 2013 Feb 12. J Psychopharmacol. 2013. PMID: 23407644 Clinical Trial.
-
Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.Int J Neuropsychopharmacol. 2009 Mar;12(2):169-79. doi: 10.1017/S1461145708009164. Epub 2008 Aug 28. Int J Neuropsychopharmacol. 2009. PMID: 18752726 Clinical Trial.
-
'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.Philos Trans R Soc Lond B Biol Sci. 2013 Feb 25;368(1615):20120407. doi: 10.1098/rstb.2012.0407. Print 2013. Philos Trans R Soc Lond B Biol Sci. 2013. PMID: 23440467 Free PMC article. Review.
Cited by
-
Fluctuations in [¹¹C]SB207145 PET binding associated with change in threat-related amygdala reactivity in humans.Neuropsychopharmacology. 2015 May;40(6):1510-8. doi: 10.1038/npp.2014.339. Epub 2015 Jan 6. Neuropsychopharmacology. 2015. PMID: 25560201 Free PMC article. Clinical Trial.
-
The subcortical and neurochemical organization of the ventral and dorsal attention networks.Commun Biol. 2022 Dec 7;5(1):1343. doi: 10.1038/s42003-022-04281-0. Commun Biol. 2022. PMID: 36477440 Free PMC article.
-
Difficult lives explain depression better than broken brains.Mol Psychiatry. 2024 Jan;29(1):206-209. doi: 10.1038/s41380-024-02462-3. Epub 2024 Feb 19. Mol Psychiatry. 2024. PMID: 38374359 No abstract available.
-
Insights into the Involvement and Therapeutic Target Potential of the Dopamine System in the Posttraumatic Stress Disorder.Mol Neurobiol. 2023 Jul;60(7):3708-3723. doi: 10.1007/s12035-023-03312-z. Epub 2023 Mar 18. Mol Neurobiol. 2023. PMID: 36933147 Review.
-
Nausea in the peri-traumatic period is associated with prospective risk for PTSD symptom development.Neuropsychopharmacology. 2019 Mar;44(4):668-673. doi: 10.1038/s41386-018-0276-5. Epub 2018 Nov 21. Neuropsychopharmacology. 2019. PMID: 30464257 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical